Can a common T2D drug stop ketoacidosis risk in type 1 diabetes?
NCT ID NCT07056699
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 3 times
Summary
This study looks at whether adding pioglitazone (a type 2 diabetes drug) to dapagliflozin (an SGLT2 inhibitor) can reduce the liver's glucose production, fat breakdown, and ketone production in people with type 1 diabetes. These effects from dapagliflozin can raise the risk of ketoacidosis, a dangerous condition. The study will involve 24 adults with type 1 diabetes and poor blood sugar control, using tracer infusions to measure changes over 16 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE1DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Diabetes Institute
RECRUITINGSan Antonio, Texas, 78229-3900, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new sensor track blood sugar with pinpoint accuracy?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- Carb showdown: which diet best controls type 1 diabetes?
- Morning workout may burn more fat and stabilize blood sugar in type 1 diabetes
- Could a simple sugar help people with type 1 diabetes exercise safely?
- New study asks: is this glucose monitor a Game-Changer for diabetes?